Biotech and Pharmaceuticals Pharmaceuticals

  • NEW YORK, Nov 30- Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors LP will pay $135 million to settle a lawsuit by investors in the drugmaker Elan Corp, who said they lost money because of insider trading by one of his portfolio managers. The preliminary class-action settlement with SAC, now known as Point72 Asset Management LP, was filed on...

  • NEW YORK, Nov 30- Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors LP will pay $135 million to settle a lawsuit by investors in Elan Corp, who said they lost money on the drugmaker due to insider trading by one of his portfolio managers. It resolves class-action claims over an estimated $275 million of illegal gains that Mathew Martoma, who...

  • Sources: Valeant-Takeda deal is 'all but dead'

    Sources say the Valeant-Takeda deal is "all but dead." CNBC's Scott Wapner reports the details, as well as how the market is reacting to this news.

  • Nov 30- Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study. Unlike generic drugs, which are interchangeable with their branded counterparts, biosimilars approved by the U.S. Food and Drug Administration to date are not...

  • Nov 30- Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin met the main goal in a key study. Pfizer tested the safety and effectiveness of the drug, PF-05280014, in combination with chemotherapeutic agent paclitaxel against Herceptin and paclitaxel in previously untreated...

  • But their objections were overwhelmed by an alliance among Republicans, many Democrats and the White House for a 996- page measure that bore wins for both parties. The Senate's expected final approval next week would mark an uncommon episode of cooperation between the GOP- run 114th Congress— which plans to adjourn next week— and President Barack Obama in their...

  • Mark Trudeau, chief executive officer of Mallinckrodt Plc

    Mallinckrodt said it experienced "production issues" with a third-party manufacturer supporting its immunotherapy platform, Therakos.

  • BATTLE CREEK, Mich.— Kellogg has announced that it will no longer advertise on Breitbart.com, the website formerly run by one of President-elect Donald Trump's top aides, Steve Bannon. The food manufacturer decided to discontinue advertising on the site as soon as it was alerted by consumers to the presence of its ads, Kellogg Co. spokeswoman Kris Charles said...

  • Theranos slams big investors

    Christopher Weaver, Wall Street Journal reporter, discusses Theranos' "smart money" investors, as well as the company's recent challenges.

  • Tiffany leading in the luxury stocks: Pisani

    CNBC's Bob Pisani looks ahead at what's moving markets this morning, including materials, banks and pharmaceutical stocks.

  • Nov 29- U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis. Humira, considered the world's biggest-selling medicine, generates $15 billion in annual sales and treats rheumatoid...

  • Nov 29- U.S. biotech company Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis. As it is not possible to produce exact copies of biotech drugs made from living cells, the cheaper versions-...

  • Stocks to Watch: November 29, 2016

    Tiffany, Pfizer and Apple stocks are making moves in Tuesday's trading session.

  • WASHINGTON— Two of the Senate's most liberal lawmakers are assailing a $6.3 billion medical research bill as a gift to drug companies, even as Republican leaders prepare to try pushing the measure through the lame-duck Congress. "It's time for Congress to stand up to the world's biggest pharmaceutical companies, not give them more handouts," Sen.

  • As Congress began the final stretch of its post-election session, Warren said the 996- page measure— a top priority for GOP leaders and backed by the biomedical industry— was riddled with provisions that she called "a bunch of special giveaways" to big pharmaceutical companies. "They didn't send us here to whimper, whine or grovel," she said on the Senate floor about...

  • Which companies will benefit from biotech in Cuba?

    Jason Kolbert, Maxim Group, and Les Funtleyder, ESquared, discuss biotech opportunities in Cuba post-Castro.

  • Pisani: Banks are flattening out

    CNBC's Bob Pisani looks at the day's market action, including what is breaking market's winning streak.

  • WASHINGTON, Nov 28- Despite Republican plans to scale back federal regulation next year, the U.S. The rule, issued as temporary regulations in April, has been challenged in federal court after it helped scuttle a planned $160 billion merger between Ireland- based Allergan Plc and U.S. drugmaker Pfizer Inc.. With Republican Donald Trump in the White House and...

  • MILAN/ LONDON, Nov 25- European shares rose slightly on Friday, nearing their highest level in over two weeks, as the market was supported by a rally in drugmakers on hopes of tie-up activity in the sector. "We continue to believe that management... remains committed to Actelion as an independent company," Barclays said, while Exane said a successful buyer would need to...

  • NEW YORK— Johnson& Johnson is in early talks to buy the Swiss drugmaker Actelion Pharmaceuticals. Johnson& Johnson of New Brunkswick, New Jersey, develops drugs and manufactures medical devices and other consumer products. Shares of Johnson& Johnson rose 93 cents to $114 in afternoon trading Friday.